Nvidia’s $600 Billion Crisis: What Jensen Huang’s Exit Means for the AI Giant
In a recent turn of events that has shocked the world, Nvidia’s newest and biggest challenge yet may have nothing to do with technology. On November 12, 2026, Nvidia CEO Jensen Huang announced his resignation from the company. Following the discovery of his affair involving a woman with suspected ties to Chinese intelligence, the company that has led the revolution in artificial intelligence and is widely regarded as the powerhouse of technology has been under enormous press
Evan Wang
3 hours ago2 min read
$2.5 Trillion Wiped From Nasdaq as AI Stocks Plunge
On November 5, the Nasdaq Composite fell 5.5%, wiping out a whopping $2.5 trillion in market value from the Nasdaq-100. The cause? Rapidly increasing doubt among investors over the future of artificial intelligence investments. This decline was Nasdaq’s worst day since April 2025 and pushed the index into correction territory, which happens when a stock market index falls over 10% from its peak. Taking part in this loss were some of the largest technology companies, like Nvi
Evan Wang
4 days ago2 min read
Novartis' Heart Drug Fails Major Clinical Trial, Threatening $900 Million Partnership
On November 7, Novartis, a massive pharmaceutical company, released its phase 3 clinical trial results for pelacarsen, an experimental cardiovascular drug. Headlining the outcome was its failure to prevent serious cardiovascular events, even though it reduced a major cholesterol-related risk marker by nearly 78%. This setback doesn’t just affect Novartis, but raises concerns about all emerging therapies for heart disease and their commercial potential. Additionally, the failu
Evan Wang
5 days ago2 min read
Gilead Acquires Experimental Inflammation Drug in $1.3 Billion Deal
On October 22, pharmaceutical giant, Gilead Sciences, acquired PepStar Therapeutics’ oral inflammation drug program in a deal worth $1.275 billion in upfront cash. A primary drug involved in the agreement is HCXT-2001, an experimental treatment that is currently undergoing Phase 1 clinical trials. This acquisition marks another step in Gilead’s expansion beyond its core HIV business. HCXT-2001 targets the interleukin-23 (IL-23) receptor, which regulates immune responses asso
Evan Wang
Nov 12 min read
Alphabet Shares Plunge as AI Spending Outpaces Cash Generation
On October 28, 2026, Google parent Alphabet saw its shares plunge after the release of their third quarter earnings report. Investor concerns centered around rising artificial intelligence expenses and underwhelming advertising revenue. Alphabet’s mounting infrastructure costs have raised questions about the profitability of AI investments. Alphabet reported quarterly revenue of $127.6 billion, a 25% increase year over year but below Wall Street's expectation of $128.2 billi
Evan Wang
Oct 292 min read
Merck's Experimental Cancer Drug Extends Survival by Nearly Seven Months
Merck's (NYSE: MRK) new cancer treatment, sacituzumab tirumotecan (sac-TMT), showed improved survival in patients with advanced or recurrent endometrial cancer. This was unveiled on October 26 and could help Merck secure its place in a rapidly expanding market for targeted cancer therapies. The Phase 3 trial saw patients receiving sac-TMT achieve a median overall survival of 19 months, compared to just 12.1 months in those receiving traditional chemotherapy. This represented
Evan Wang
Oct 272 min read